{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-027445","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-07-02T20:23:41+00:00","discovered_at":"2026-07-02T20:25:00.255747+00:00","generated_at":"2026-07-02T20:25:07.166137+00:00","sec_items":["1.01","3.02","3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio raises $1B in convertible preferred equity from Sixth Street and KKR","bullets":["Sixth Street invested $800M and HCRx (KKR affiliate) invested $133.9M in Series A convertible preferred stock.","Initial conversion price of $137.79 per share (over 100% premium to 30-day VWAP); increases to $153.10 after year 5.","Preferred stock carries 7.00% annual dividend, payable in kind or cash at Company's option; no scheduled maturity.","Proceeds to accelerate launches of Attruby, BBP-418, encaleret, and infigratinib over next 12 months.","Company may redeem after year 3 at escalating premiums; conversion mandatory if stock price exceeds 200% of conversion price."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-027445","json":"https://secwatch.observer/filing/0001140361-26-027445.json","markdown":"https://secwatch.observer/filing/0001140361-26-027445.md","text":"https://secwatch.observer/filing/0001140361-26-027445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126027445/0001140361-26-027445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126027445/ef20077282_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-02T20:25:07.166137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}